150 related articles for article (PubMed ID: 22427690)
1. Various p53 mutant proteins differently regulate the Ras circuit to induce a cancer-related gene signature.
Solomon H; Buganim Y; Kogan-Sakin I; Pomeraniec L; Assia Y; Madar S; Goldstein I; Brosh R; Kalo E; Beatus T; Goldfinger N; Rotter V
J Cell Sci; 2012 Jul; 125(Pt 13):3144-52. PubMed ID: 22427690
[TBL] [Abstract][Full Text] [Related]
2. p53 Regulates the Ras circuit to inhibit the expression of a cancer-related gene signature by various molecular pathways.
Buganim Y; Solomon H; Rais Y; Kistner D; Nachmany I; Brait M; Madar S; Goldstein I; Kalo E; Adam N; Gordin M; Rivlin N; Kogan I; Brosh R; Sefadia-Elad G; Goldfinger N; Sidransky D; Kloog Y; Rotter V
Cancer Res; 2010 Mar; 70(6):2274-84. PubMed ID: 20197462
[TBL] [Abstract][Full Text] [Related]
3. Gain-of-function mutant p53 upregulates CXC chemokines and enhances cell migration.
Yeudall WA; Vaughan CA; Miyazaki H; Ramamoorthy M; Choi MY; Chapman CG; Wang H; Black E; Bulysheva AA; Deb SP; Windle B; Deb S
Carcinogenesis; 2012 Feb; 33(2):442-51. PubMed ID: 22114072
[TBL] [Abstract][Full Text] [Related]
4. Up-regulation of NFkappaB-responsive gene expression by DeltaNp73alpha in p53 null cells.
Tanaka Y; Ota K; Kameoka M; Itaya A; Yoshihara K
Exp Cell Res; 2006 May; 312(8):1254-64. PubMed ID: 16430884
[TBL] [Abstract][Full Text] [Related]
5. Tumor-derived p53 mutants induce NF-kappaB2 gene expression.
Scian MJ; Stagliano KE; Anderson MA; Hassan S; Bowman M; Miles MF; Deb SP; Deb S
Mol Cell Biol; 2005 Nov; 25(22):10097-110. PubMed ID: 16260623
[TBL] [Abstract][Full Text] [Related]
6. The growth-inhibitory function of p53 is separable from transactivation, apoptosis and suppression of transformation by E1a and Ras.
Hansen RS; Braithwaite AW
Oncogene; 1996 Sep; 13(5):995-1007. PubMed ID: 8806689
[TBL] [Abstract][Full Text] [Related]
7. A systematic search for downstream mediators of tumor suppressor function of p53 reveals a major role of BTG2 in suppression of Ras-induced transformation.
Boiko AD; Porteous S; Razorenova OV; Krivokrysenko VI; Williams BR; Gudkov AV
Genes Dev; 2006 Jan; 20(2):236-52. PubMed ID: 16418486
[TBL] [Abstract][Full Text] [Related]
8. NF-kappaB: tumor promoter or suppressor?
Perkins ND
Trends Cell Biol; 2004 Feb; 14(2):64-9. PubMed ID: 15102437
[TBL] [Abstract][Full Text] [Related]
9. Modulation of gene expression by tumor-derived p53 mutants.
Scian MJ; Stagliano KE; Ellis MA; Hassan S; Bowman M; Miles MF; Deb SP; Deb S
Cancer Res; 2004 Oct; 64(20):7447-54. PubMed ID: 15492269
[TBL] [Abstract][Full Text] [Related]
10. The properties of p53 proteins selected for the loss of suppression of transformation.
Olson DC; Levine AJ
Cell Growth Differ; 1994 Jan; 5(1):61-71. PubMed ID: 8123594
[TBL] [Abstract][Full Text] [Related]
11. The p53 tumor suppressor gene and gene product.
Levine AJ
Princess Takamatsu Symp; 1989; 20():221-30. PubMed ID: 2488233
[TBL] [Abstract][Full Text] [Related]
12. Mutant p53 induces the GEF-H1 oncogene, a guanine nucleotide exchange factor-H1 for RhoA, resulting in accelerated cell proliferation in tumor cells.
Mizuarai S; Yamanaka K; Kotani H
Cancer Res; 2006 Jun; 66(12):6319-26. PubMed ID: 16778209
[TBL] [Abstract][Full Text] [Related]
13. Malignant transformation of rat embryo fibroblasts by cotransfection with eleven human mutant p53 cDNAs and activated H-ras gene.
Kikuchi-Yanoshita R; Tanaka K; Muraoka M; Konishi M; Kawashima I; Takamoto S; Hirai H; Miyaki M
Oncogene; 1995 Oct; 11(7):1339-45. PubMed ID: 7478555
[TBL] [Abstract][Full Text] [Related]
14. Localization of a mutant p53 response element on the tissue inhibitor of metalloproteinase-3 promoter: mutant p53 activities are distinct from wild-type.
Thomas S; Reisman D
Cancer Lett; 2006 Aug; 240(1):48-59. PubMed ID: 16236433
[TBL] [Abstract][Full Text] [Related]
15. p53 mutations, ras mutations, and p53-heat shock 70 protein complexes in human lung carcinoma cell lines.
Lehman TA; Bennett WP; Metcalf RA; Welsh JA; Ecker J; Modali RV; Ullrich S; Romano JW; Appella E; Testa JR
Cancer Res; 1991 Aug; 51(15):4090-6. PubMed ID: 1855224
[TBL] [Abstract][Full Text] [Related]
16. Activated oncogenes promote and cooperate with chromosomal instability for neoplastic transformation.
Woo RA; Poon RY
Genes Dev; 2004 Jun; 18(11):1317-30. PubMed ID: 15175263
[TBL] [Abstract][Full Text] [Related]
17. Identification and characterization of genes whose expressions are altered in rat 6 fibroblasts transformed by mutant p53(val135).
Yam JW; Zheng JY; Hsiao WL
Biochem Biophys Res Commun; 1999 Dec; 266(2):472-80. PubMed ID: 10600527
[TBL] [Abstract][Full Text] [Related]
18. [Protein p53 inhibits the activity of the enhancer of the immediate-early genes of murine cytomegalovirus].
Lembo D; Angeretti A; Cavallo R; Gariglio M; Gribaudo G; Landolfo S
G Batteriol Virol Immunol; 1994; 86(1-12):43-54. PubMed ID: 8706975
[TBL] [Abstract][Full Text] [Related]
19. Potential microRNA therapies targeting Ras, NFkappaB and p53 signaling.
Kasinski AL; Slack FJ
Curr Opin Mol Ther; 2010 Apr; 12(2):147-57. PubMed ID: 20373258
[TBL] [Abstract][Full Text] [Related]
20. Mutant p53 expression enhances drug resistance in a hepatocellular carcinoma cell line.
Chan KT; Lung ML
Cancer Chemother Pharmacol; 2004 Jun; 53(6):519-26. PubMed ID: 15004724
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
